Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5)
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: Transporters in the plasma membrane have been exploited successfully for the delivery of drugs in the form of prodrugs and nanoparticles. Organic cation/carnitine transporter 2 (OCTN2, SLC22A5) has emerged as a viable target for drug delivery. OCTN2 is a Na+-dependent high-affinity transporter for L-carnitine and a Na+-independent transporter for organic cations. OCTN2 is expressed in the blood-brain barrier, heart, liver, kidney, intestinal tract and placenta and plays an essential role in L-carnitine homeostasis in the body.Areas covered: In recent years, several studies have been reported in the literature describing the utility of OCTN2 to enhance the delivery of drugs, prodrugs and nanoparticles. Here we summarize the salient features of OCTN2 in terms of its role in the cellular uptake of its physiological substrate L-carnitine in physiological and pathological context; the structural requirements for recognition and the recent advances in OCTN2-targeted drug delivery systems, including prodrugs and nanoparticles, are discussed.Expert opinion: This transporter has great potential to be utilized as a target for drug delivery to improve oral absorption of drugs in the intestinal tract. It also has potential to facilitate the transfer of drugs across the biological barriers such as the blood-brain barrier, blood-retinal barrier, and maternal-fetal barrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“The concentration of L-carnitine in the liver could be up to 1 mM [36,40,41]; as OCTN2 is expressed in the liver, the concentration of L-carnitine in this tissue arises not only from the endogenous synthesis but also from uptake of L-carnitine present in the blood.”
BackgroundSingh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368
Self-citationMechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294
Muoio, D. M., Noland, R. C., Kovalik, J.-P., Seiler, S. E., Davies, M. N., DeBalsi, K. L., Ilkayeva, O. R., Stevens, R. D., Kheterpal, I., Zhang, J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.005 · Cited by 372 · cited 1×
“[73], and lipid-induced insulin resistance is proposed to be the key event in the link [73–75].”
BackgroundCARNITINE METABOLISM AND ITS REGULATION IN MICROORGANISMS AND MAMMALS
Rebouche, C. J., & Seim, H. (1998) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.18.1.39 · Cited by 362 · cited 1×
“The concentration of L-carnitine in blood is about 50 μM [36,37].”
Backgroundβ-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter
Ganapathy, M. E., Huang, W., Rajan, D. P., Carter, A. L., Sugawara, M., Iseki, K., Leibach, F. H., & Ganapathy, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.1699 · Cited by 175
Self-citationTamai, I. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1816 · Cited by 141
Yao, Q., Dai, Z., Hoon Choi, J., Kim, D., & Zhu, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b09511 · Cited by 71
Self-citationMalaguarnera, M., Vacante, M., Motta, M., Giordano, M., Malaguarnera, G., Bella, R., Nunnari, G., Rampello, L., & Pennisi, G. (2011) · Metabolic Brain Disease · doi:10.1007/s11011-011-9260-z · Cited by 61
Cited by
Brown, T. P., & Ganapathy, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107451 · Cited by 481
Self-citationA guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
Li, N., & Zhao, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.689042 · Cited by 79
“consequences such as cardiac and skeletal myopathy, cardiac hypertrophy and NAFLD (28).”
BackgroundResearch and development of drug delivery systems based on drug transporter and nano-formulation
Peng, Y., Chen, L., Ye, S., Kang, Y., Liu, J., Zeng, S., & Yu, L. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.02.004 · Cited by 62
Metadata
- Authors
- Kou, L., Sun, R., Ganapathy, V., Yao, Q., & Chen, R.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-07-23
- Volume
- 22
- Issue
- 8
- Pages
- 715-726
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2883965199
- Cited by
- 58
- References
- 9
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). https://app.cochat.ai/papers/10.1080/14728222.2018.1502273
- The paper
- Kou, L., Sun, R., Ganapathy, V., Yao, Q., & Chen, R. (2018). Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5). Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1502273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.